LUMEOVA’s Post

𝗡𝗮𝗻𝗼𝘁𝗲𝗰𝗵 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗥𝗮𝗶𝘀𝗲𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗨.𝗦. - 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟭𝘀𝘁-𝟭𝟱𝘁𝗵, 𝟮𝟬𝟮𝟰 An interesting transaction closed in the Nanotech sector over the past two  weeks. If you would like more information about these deals or wish to discuss the capital-raising market for your company, please contact me. 𝗟𝗮𝘁𝗲𝗿 𝗦𝘁𝗮𝗴𝗲 𝗩𝗖 𝟭. 𝗠𝗲𝘁𝗢𝘅 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹, a manufacturer of superconducting wire designed to transmit electricity without electrical loss or generate heat during operation, raised $40  million in Series B venture funding in a deal led by New System Ventures and Centaurus Capital. The funds will be used to revolutionize the energy and technology sectors with the company’s advanced power delivery technology and accelerate delivery for its customers and partners. #castleplacement #capitalraising #privateequity #venturecapital #investment #Nanotech

This is great news for the Spanish deep tech sector as well as for the companies working with graphene as we do. We all have to cherish when news like these happen in our community (phisically & industry). INBRAIN Neuroelectronics has been able to successfully demonstrate that investing in deep tech will pay off in the long term. Congrats to their founders and "Marshalls" in the company Carolina Aguilar & professor Jose Antonio Garrido. INBRAIN Neuroelectronics was a spin off from the Institut Català de Nanociència i Nanotecnologia in Barcelona that has been able to showcase value to investors by achieving one of the (if not "the") largest B series that I can remember in Spain in Deep Tech. Moreover, though, the inventions behind the company, will hopefully one day benefit real patients. Therefore, it is not about investing in "cool" projects, but also in the meaningful ones that can actually create a better tomorrow for all of us. Enjoy the weekend! PS: From Graphenicalab S.L. we wish you: ... Keep on moving INBRAIN Neuroelectronics!! #graphene #innovation #seriesB #deeptech #valuecreation

📅 Investor webinar | Friday 11th October at 1 PM BST 🕒 As we’ve recently shared, we’re raising investment on Crowdcube to support our rapid growth and exciting expansion plans. With strong interest in the campaign, we’re hosting a webinar with a Q&A session to share more about Proteus and give investors the opportunity to speak directly with our CEO, Drew Blaxland. We warmly invite anyone in our network and community interested in becoming a Proteus shareholder to register below. https://lnkd.in/eHKUGS_b We look forward to seeing you on Friday. You can also contact Drew Blaxland directly with any questions in the meantime. #ProteusMarineRenewables #Proteus #Crowdfunding #RenewableEnergy #TidalTechnology #NetZero #CleanTech #InnovativeTech #Sustainability Don’t invest unless you’re prepared to lose all the money you invest. This is a high risk investment.

Atlas Venture, which counts 56 portfolio biotechs, is looking at keeping its 14th fund the same size as its 13th: $450 million. The firm had progressively increased the size of its last few funds but is looking at a "disciplined" new fund, according to an annual review presentation posted on Monday, Nov. 18. Atlas raised $280 million for its 10th fund in 2015, $350 million in 2017, $400 million in 2020 and then $450 million for its 13th batch in 2022. Atlas has been quite active in 2024. It has disclosed investments in about a dozen private biotechs, according to the presentation. One of those, obesity biotech Kailera, secured one of the industry’s largest private funding rounds of this year. About 10 more have been made in stealth mode, according to the presentation. #biotech #biotechventurecapital #lifesciencesvc #biotechvc #atlasventure

Is your focus on creating value or impression? How can you focus more on the longevity of value over the passing waves of impression? #MoreClearEveryDay #GettinClear #PowerOfCompounding #LittleByLittle #AtomicHabits

EMV Capital passes £100m FUM milestone @EMVCapital #AIM #EMVC. EMV Capital (AIM:EMVC) PLC, the tech and life sciences venture capital group formerly known as NetScientific, passed a significant milestone in the first half as assets under management exceeded £100 million. The exact figure, £106.7 million, was up sharply from the £61.6 million posted this time last year. Within that overall number, there was a 12% increase in the fair value of its direct holdings, for third-party assets growth was a stellar 71%, while there was an addition of £24.1 million from the Martlet Capital portfolio as well as a £3.2 million increase in the managed portfolio. EMV's... http://ow.ly/RWYs105KorK

The SOLIVUS crowdfund campaign has been a success and is now in closing phase. This is the last chance to invest or increase your investment in Solivus.   Click here: https://lnkd.in/eft-kEf6   We look forward to providing our investors regular updates on our growth and progress as we scale.   Thank you so much to everyone who has invested, joining us on our adventure to decarbonise the built environment with lightweight solar. ☀🌱 Crowdcube is regulated - you should not invest unless you're prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. #crowdcube #crowdfunding #investment #funding

EMV Capital plc (AIM:EMVC) , the tech and life sciences venture capital group formerly known as NetScientific, passed a significant milestone in the first half as assets under management exceeded £100 million. The exact figure, £106.7 million, was up sharply from the £61.6 million posted this time last year. Within that overall number, there was a 12% increase in the fair value of its direct holdings, for third-party assets growth was a stellar 71%, while there was an addition of £24.1 million from the Martlet Capital portfolio as well as a £3.2 million increase in the managed portfolio. EMV's portfolio now spans an impressive 70 companies.  CEO, Dr Ilian Iliev, said despite "challenging" market conditions, the company has protected shareholder value and bolstered its portfolio through £6.4m in syndicated fundraising, "proactive management, and our hands-on value creation services". He added: "The group is now... More at #Proactive #ProactiveInvestors http://ow.ly/RWYs105KorK

NetScientific is pleased to announce that its wholly owned venture capital and corporate finance firm, EMV Capital , has been appointed as investment manager to Martlet Capital to manage on a discretionary basis its c.£23.3m portfolio of investments, and has acquired its operational VC business. Having worked closely with Martlet Capital since incorporation, EMV Capital recently identified the opportunity to take on the investment management role for Martlet Capital, using its active management strategy to accelerate and maximise returns for the shareholders of Martlet Capital. The transaction provides to NetScientific Group an additional c.£23.3m of funds under management (an increase of c.89%), recurring investment management fees for a minimum period of four years; and carried interest over the Martlet Portfolio. Dr ILIAN ILIEV, CEO of NetScientific and MD of EMV Capital, commented: “This non-dilutive transaction represents an important milestone for the NetScientific group, aligned with our objectives to become a leading deep tech and life sciences venture capital investor in the UK and Europe. This important fund management mandate and acquisition of the Martlet business significantly increases the fee income and critical mass of our funds practice. We also gain ‘work in progress’ for the potential launch of two further funds under the Martlet brand and a supportive Martlet investor base.'' Read the full announcement: https://lnkd.in/gbDt-FsA #aim #venturecapital #acquisition #deeptech #lifesciences

We wrote about Atlas Venture's 14th fund a few weeks ago, noting they were eyeing a $450 million pool focused on "discipline." The storied biotech investment firm made it official today (saying they've closed on the raise), and Bruce Booth writes about the "VC Math Problem" in a blog post (linked in comments) #biotechvc #biotechstartups #biotechinvesting